PFG Advisors Sells 2,157 Shares of Danaher Co. (NYSE:DHR)

PFG Advisors reduced its position in shares of Danaher Co. (NYSE:DHR) by 9.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,321 shares of the conglomerate’s stock after selling 2,157 shares during the quarter. PFG Advisors’ holdings in Danaher were worth $5,928,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Magnus Financial Group LLC purchased a new stake in shares of Danaher during the third quarter worth about $233,000. First Pacific Financial grew its position in shares of Danaher by 3.7% in the 3rd quarter. First Pacific Financial now owns 3,877 shares of the conglomerate’s stock worth $1,078,000 after buying an additional 139 shares during the last quarter. Cabot Wealth Management Inc. increased its stake in shares of Danaher by 2.4% during the third quarter. Cabot Wealth Management Inc. now owns 27,104 shares of the conglomerate’s stock valued at $7,535,000 after buying an additional 639 shares during the period. Trust Co. of Oklahoma raised its holdings in shares of Danaher by 4.1% during the third quarter. Trust Co. of Oklahoma now owns 25,512 shares of the conglomerate’s stock valued at $7,093,000 after acquiring an additional 1,004 shares in the last quarter. Finally, Norway Savings Bank lifted its stake in Danaher by 8.2% in the third quarter. Norway Savings Bank now owns 5,589 shares of the conglomerate’s stock worth $1,554,000 after acquiring an additional 424 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Robert W. Baird boosted their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen increased their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Stephens assumed coverage on Danaher in a report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price on the stock. Finally, The Goldman Sachs Group raised their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Stock Up 0.4 %

Shares of Danaher stock opened at $272.68 on Wednesday. The company has a 50-day simple moving average of $270.43 and a two-hundred day simple moving average of $259.59. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $201.97 billion, a PE ratio of 46.22, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business earned $2.05 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s payout ratio is 18.31%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.